Patent Application
20240342102
This application is based on and claims priority to CN Patent Application No. 202010789585.5 filed Aug. 7, 2020, which application is incorporated herein by reference in its entirety.
The invention relates to the field of pharmaceutical chemistry, in particular to obizidine fumarate enteric-coated pellets, and preparation therefor and use thereof in manufacture of a medication for the prevention and/or treatment of tumors.
Obizidine fumarate, with a chemical name of (4-benzyl-[1,4]diazocycloheptan-1-yl)-acetyl (3-allyl-2-hydroxy-methylenephenyl) hydrazine fumarate, has a chemical formula of:
WO2010102513A1 disclosed the structure, preparation and use of obizidine fumarate and its derivatives, which can specifically activate procasapase-3 in tumor cells to active caspase-3, and thus induce tumor cell apoptosis. This document also further disclosed that these compounds have significant inhibitory effects on the growth of various cancer cell lines, such as HL-60 cells, NCI-H460 cells, HepG2 cells, and A549 cells. As the expression of procaspase-3 in tumor cells is much higher than that in normal cells, obizidine fumarate is expected to become a new anti-tumor drug regulating apoptosis signal transduction pathway.
The inventor of this application has conducted extensive researches on the formulation and preparation of obizidine fumarate, and developed an enteric coated pellets preparation of obizidine fumarate. The excipients used in this preparation have good compatibility with obizidine fumarate, and the preparation showed good stability, high safety, rapid disintegration and stable release in intestinal fluid, and thus the bioavailability of obizidine fumarate are enhanced. The enteric coated pellets are prepared by extrusion spheronization process, which is conducive to expanding the drug loading range of the pellets, facilitating the adjustment of the dosage specifications of the pellets according to clinical needs, and realizing industrial production, with short time consumption and good effect.
In the first aspect, the invention provides enteric coated pellets of obizidine fumarate; in the second aspect, the invention provides capsules or tablets containing the enteric coated pellets; in the third aspect, the invention provides a method for preparation of the enteric coated pellets; in the fourth aspect, the invention provides a use of the enteric coated pellets or the capsules or tablets in preparation of a medication for preventing and/or treating tumors; in the fifth aspect, the invention provides a use of the enteric coated pellets or capsules or tablets for the prevention and/or treatment of tumors; and in the sixth aspect, the invention provides a method of treatment of tumors, including administering the enteric coated pellets or the capsules or tablets in a therapeutically effective amount to a subject in need.
Specifically, in the first aspect, the invention provides an enteric coated pellet of obizidine fumarate, which comprises a) a pellet core containing obizidine fumarate, b) an isolation layer and c) an enteric coated layer.
In some embodiments, the pellet core also comprises a diluent, disintegrant and cosolvent.
In other embodiments, the diluent is selected from one or more of microcrystalline cellulose, lactose and pregelatinized starch.
In other embodiments, the diluent is microcrystalline cellulose.
In other embodiments, the diluent is lactose.
In other embodiments, the diluent is pregelatinized starch.
In other embodiments, the disintegrant is selected from one or more of sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked povidone.
In other embodiments, the cosolvent is selected from one or more of polyvinylpyrrolidone, Tween-20, Tween-60, Tween-80, and sodium dodecyl sulfate.
In other embodiments, the cosolvent is polyvinylpyrrolidone.
In other embodiments, the cosolvent is Tween-20.
In other embodiments, the cosolvent is Tween-60.
In other embodiments, the cosolvent is Tween-80.
In other embodiments, the cosolvent is sodium dodecyl sulfate.
In other embodiments, the cosolvent is a combination of polyvinylpyrrolidone and Tween-20.
In some embodiments, the diluent in the pellet core is selected from one or more of microcrystalline cellulose, lactose, and pregelatinized starch; the disintegrant is selected from one or more of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and cross-linked povidone; and the cosolvent is selected from one or more of polyvinylpyrrolidone, Tween-20, Tween-60, Tween-80, and sodium dodecyl sulfate.
In other embodiments, the disintegrant is:
In other embodiments, the disintegrant is sodium carboxymethyl starch.
In other embodiments, the disintegrant is cross-linked sodium carboxymethyl cellulose.
In other embodiments, the disintegrant is cross-linked povidone.
In other embodiments, the disintegrant is a combination of low substituted hydroxypropyl cellulose and sodium carboxymethyl starch.
In other embodiments, in the combination of low substituted hydroxypropyl cellulose and sodium carboxymethyl starch, the mass ratio of the low substituted hydroxypropyl cellulose to sodium carboxymethyl starch is 0.1-3.5:1, such as 0.5:1, 1:1, 1.4:1, 1.5:1, 1.75:1, 2:1, 2.3:1, 2.5:1 or 3:1.
In other embodiments, the disintegrant is a combination of low substituted hydroxypropyl cellulose and cross-linked sodium carboxymethyl cellulose.
In other embodiments, in the combination of low substituted hydroxypropyl cellulose and cross-linked sodium carboxymethyl cellulose, the mass ratio of the low substituted hydroxypropyl cellulose and the cross-linked sodium carboxymethyl cellulose is 0.1-3.5:1, such as 0.5:1, 1:1, 1.4:1, 1.5:1, 1.75:1, 2:1, 2.3:1, 2.5:1 or 3:1.
In other embodiments, the disintegrant is a combination of low substituted hydroxypropyl cellulose and cross-linked povidone.
In other embodiments, in the combination of low substituted hydroxypropyl cellulose and cross-linked povidone, the mass ratio of the low substituted hydroxypropyl cellulose and the cross-linked povidone is 0.1-3.5:1, such as 0.5:1, 1:1, 1.4:1, 1.5:1, 1.75:1, 2:1, 2.3:1, 2.5:1 or 3:1.
In other embodiments, the pellet core comprises, by weight:
In other embodiments, the pellet core comprises, by weight:
In other embodiments, the pellet core comprises, by weight:
In some embodiments, the isolation layer comprises isolation materials,
In some embodiments, the isolation material is one or two of hydroxypropyl methylcellulose and hydroxypropyl cellulose.
In some embodiments, the isolation material is hydroxypropyl methyl cellulose.
In some embodiments, the isolation material is hydroxypropyl cellulose.
In some embodiments, the isolation material is a combination of hydroxypropyl methyl cellulose and hydroxypropyl cellulose.
In some embodiments, the anti-adhesive in the isolation layer is talcum powder.
In some embodiments, the enteric layer comprises an enteric coating material,
Optionally, the enteric coating also includes a plasticizer and/or an anti-adhesive.
In some embodiments, the enteric coating material is selected from one or more of acrylic resin, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, and cellulose acetate phthalate.
In some embodiments, the enteric coating material is acrylic resin.
In some embodiments, the enteric coating material is hydroxypropyl methylcellulose acetate succinate.
In some embodiments, the enteric coating material is hydroxypropylmethylcellulose phthalate.
In some embodiments, the enteric coating material is cellulose acetate phthalate.
In some embodiments, the plasticizer is triethyl citrate.
In some embodiments, the anti-adhesive in the enteric layer is talcum powder or glyceryl monostearate or a combination thereof.
In some embodiments, the anti-adhesive in the enteric layer is talcum powder.
In some embodiments, the anti-adhesive in the enteric layer is glyceryl monostearate.
In some embodiments, the anti-adhesive in the enteric layer is a combination of talcum powder and glyceryl monostearate.
In some embodiments, the enteric coated pellet comprises: a) a pellet core containing obizidine fumarate, b) an isolation layer, and c) an enteric coated layer, with the mass percentage of them being as follows:
In other embodiments, a pellet core containing obizidine fumarate, b) an isolation layer, and c) an enteric coated layer, with the mass percentage of them being as follows:
In some embodiments, the weight of the isolation layer of the enteric coated pellet is 10%-20% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the weight of the isolation layer of the enteric coated pellet is 14%-20% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the weight of the isolation layer of the enteric coated pellet is 14%-18% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the weight of the isolation layer of the enteric coated pellet is 14%-16% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the weight of the enteric layer of the enteric coated pellet is 16%-26% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the weight of the enteric layer of the enteric coated pellet is 16%-20% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the weight of the enteric layer of the enteric coated pellet is 17%-20% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the weight of the enteric layer of the enteric coated pellet is 18%-20% of the weight of the pellet core containing obizidine fumarate.
In some embodiments, the enteric coated pellet comprises, by weight:
In some embodiments, the enteric coated pellet comprises, by weight:
In some embodiments, the pellet size of the enteric coated pellet is between 0.3-1.5 mm.
In some embodiments, the obizidine fumarate in the enteric coated pellet is of amorphous, crystalline form A or crystalline form B.
In some embodiments, the particle size D90 of obizidine fumarate particles in the enteric coated pellet is less than or equal to 50 μm.
In other embodiments, the particle size D90 of obizidine fumarate particles in the enteric coated pellet is less than or equal to 30 μm.
In the second aspect, the invention provides a capsule or tablet, which is encapsulated or tableted from the enteric coated pellet of any one of the preceding embodiments.
In other embodiments, the content of obizidine fumarate in the capsule or tablet is 0-200 mg.
In other embodiments, the content of obizidine fumarate in the capsule or tablet is 5 mg, 10 mg, 25 mg, 50 mg, 100 mg or 200 mg.
In the third aspect, the invention provides a method for preparation of the enteric coated pellets, which method comprises the steps of:
In the fourth aspect, the invention provides a use of the enteric coated pellet or the capsule or tablet in preparation of a medication for prevention and/or treatment of tumors.
In the fifth aspect, the invention provides a use of the enteric coated pellets or capsules or tablets for the prevention and/or treatment of tumors.
In the sixth aspect, the invention provides a method for treatment of tumors, wherein the method comprises administering the enteric coated pellet or the capsule or tablet in a therapeutically effective amount to a subject in need.
In some embodiments, the tumors are acute promyelocytic leukemia, large cell lung cancer, liver cancer or non-small cell lung cancer.
Before describing the invention in more detail, it should be understood that the invention is not limited to the specific embodiments described herein, because such embodiments can be modified or changed. It should also be understood that the terms used herein are for the purpose of describing specific embodiments only, and are not used for limitation. Unless otherwise specified, all technical and scientific terms used herein have the same meanings generally understood by those skilled in the art. All publications and patents referenced herein are incorporated herein in their entirety by reference.
The terms “mass percentage”, “weight percentage” or “percentage by weight” or “wt %” are defined as the weight of a single component in a preparation divided by the total weight of all components in the preparation and multiplied by 100%. In the invention, “%” refers to the mass percentage unless otherwise specified.
In the description presented above, all figures disclosed herein are approximate regardless of whether the word “approximately” or “about” is used. The value of each figure may have a difference of less than 10% or a reasonable difference considered by a person of skills in the art, such as 1%, 2%, 3%, 4% or 5%.
The term “D90” refers to the particle size corresponding to 90% of the cumulative particle size distribution of a sample. Its physical meaning is that 90% of the particles are smaller than it, for example, “D90 is less than or equal to 50 μM” means that the particles with a particle size is not greater than 50 μm account for 90.
The term “AUC0-∞” refers to the area under the concentration time curve (AUC) extrapolated to infinity or AUC+ (the last measured concentration/elimination rate constant) to the time point of the last measurement.
The term “Cmax” is defined as the maximum plasma concentration of the active ingredient measured.
The preparation provided by the invention can be given to patients alone, or given together or in combination with other active preparations. The terms “co-administration” and “combination” include the simultaneous or sequential administration of two or more therapeutic agents without a specific time limit. In one embodiment, the reagent simultaneously exists in cells or individuals, or simultaneously exerts biological or therapeutic effects. In one embodiment, each of therapeutic agents is in the same composition or unit dosage form. In other embodiments, each of the therapeutic agents is in different composition or unit dosage form. In some embodiments, before administration of the second therapeutic agent (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks ago), the first agent is given simultaneously or later (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks later).
The term “diluent” includes but is not limited to microcrystalline cellulose, lactose, compressible sugar, dextrose, mannitol, dextrin, maltodextrin, sorbitol, xylitol, sodium chloride, calcium carbonate, magnesium carbonate, calcium phosphate, calcium sulfate, magnesium oxide, kaolin, powdered cellulose, pregelatinized starch, starch, barium sulfate, magnesium trisilicate, aluminum hydroxide and combinations thereof. In some embodiments, the diluent of the invention comprises at least microcrystalline cellulose. In other embodiments, the diluent of the invention includes microcrystalline cellulose and one or more of selected from mannitol, lactose, lactose monohydrate, pregelatinized starch, sorbitol, calcium hydrogen phosphate, starch and sucrose.
The term “disintegrant” includes but is not limited to corn starch, sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone (cross-linked povidone, PVP), alginate, sodium alginate, guar gum, etc.
The term “cosolvent” includes but is not limited to sodium benzoate, citric acid, calcium lactate, ethanol, isooctanol, polyvinylpyrrolidone, Tween-20, Tween-60, Tween-80, sodium dodecyl sulfate, etc.
The beneficial effects of the invention include:
The following will further explain the substantive content of the invention in combination with the specific embodiments of the invention. It should be understood that the following embodiments are only used to explain the invention, but not to limit the protection scope of the invention. If the specific conditions are not indicated in the following examples, the general conditions or the manufacturer's recommendations shall be followed. The raw materials used without specifying the manufacturer are all conventional products that can be purchased in the market.
Although many materials and operation methods used in the following embodiments are well known in the art, some are still described herein as much detail as possible. It is clear to those skilled in the art that, unless otherwise specified, the materials and operation methods used in the following embodiments are well known in the art.
In the following embodiments: rpm refers to revolutions per minute; RRT refers to relative retention time; Min is minute; ND means no detection; DCPA refers to anhydrous calcium hydrogen phosphate; MCC PH200 is microcrystalline cellulose PH200; SDS means sodium dodecyl sulfate; HPMC-AS refers to hydroxypropyl methylcellulose acetate succinate; HPMCP refers to hydroxypropyl methylcellulose phthalate; API refers to obizidine fumarate; SD refers to standard deviation.
The reagents used in the invention can be purchased from the market or prepared by the method described in the invention. Obizidine fumarate was purchased from Dongguan Chang'an Dongyangguang Pharmaceutical Research and Development Co., Ltd., microcrystalline cellulose was purchased from Asahi Kasei, Japan, sodium carboxymethyl starch was purchased from Anhui Shanhe Auxiliary Materials Co., Ltd., low substituted hydroxypropyl cellulose was purchased from Anhui Shanhe Auxiliary Materials Co., Ltd., Tween 20/Tween 80 was purchased from Nanjing Weier Chemicals, Polyvinylpyrrolidone (k30) was purchased from Ashland, and pregelatinized starch was purchased from Rogate, Hydroxypropyl methylcellulose (E3) was purchased from Anhui Shanhe Auxiliary Materials Co., Ltd., talcum powder was purchased from Guangxi Longsheng Huamei Talc Development Co., Ltd., hydroxypropyl methylcellulose acetate (LG) was purchased from Ashland/Shinyue, Japan, triethyl citrate was purchased from Bengbu Fengyuan Tushan Pharmaceuticals Co., Ltd., and glycerol monostearate was purchased from Hunan Erkang Pharmaceuticals.
First, pre-treatment: Obizidine fumarate API passes through YK-60 equipment swing granulator (Changsha Yi Pharmaceutical Machinery Co., Ltd.), through 24 mesh screen, and is pretreated for standby; Second, soft material mixing: 1125.10 g of pretreated API, 625.12 g of microcrystalline cellulose, 200.20 g of sodium carboxymethyl starch and 350.32 g of low substituted hydroxypropyl cellulose were added to a wet granulating machine (Shenzhen Xinyit Technology Co., Ltd.), and mixed for 5 minutes at the rotating speed of the stirring paddle of 1-3 rps and the cutting knife of 10-40 rps. Add a ethanol (60%, 900 ml) solution of 75.12 g of polyvinylpyrrolidone (k30) and 125.37 g of Tween 20, set the speed of the stirring paddle to 1-3 rps, and the speed of the cutting knife to 20-60 rps, and stop mixing and cutting after adding.
Third, extrusion and spheronization: the soft materials prepared in the second step are extruded through 0.3-1.5 mm orifice plates with an extrusion and spheronization machine (Shenzhen Xinyit Technology Co., Ltd.), and then spheronized in the way of first high speed (600-1600 rpm) and then low speed (100-500 rpm). The high speed spheronization time and low speed spheronization time are adjusted according to the specific situation. During the spheronization process, an appropriate amount of 60%-95% ethanol can be sprayed to help the pellet molding.
Fourth, drying: the pellets (wet materials) prepared by spheronization are dried in a fluidized bed (Shenzhen Xinyite Technology Co., Ltd.). The inlet air temperature is 45° C., the material temperature is controlled at 35-45° C., and the drying time is about 30 min.
Fifth, isolation coating
Preparation of coating solution: Heat about ½ of the purified water with the prescription amount to about 60° C., stir it into a vortex, slowly add 241.12 g of hydroxypropyl methyl cellulose for dispersion, then add the remaining purified water (at room temperature), stir until the solution is clear, and then add talcum powder and stir for 30 min for standby; Coating: Put the plain pellets into the fluidized bed, set the fan speed at 1750-2000 rpm, set the air inlet temperature at 40-50° C., which can be adjusted according to the actual situation.
Preheat the pellets, control the material temperature at 37-39° C., and then start the atomization pressure at 0.13-0.18 Mpa. Start the peristaltic pump to start spraying liquid. The spraying speed increases from slow to fast, and the peristaltic pump speed is controlled at 8-12 rpm (pipe inner diameter is 5 mm). Pay attention to monitoring the material temperature and fluidization state during coating, and the parameters can be adjusted according to the actual situation to prevent the pellet adhesion.
Sixth, enteric coating
Preparation of coating solution: Stir the weighed absolute ethanol into a vortex, slowly add 227.02 g of hydroxypropyl methylcellulose acetate succinate for swelling, slowly add purified water (cold water), stir until the solution is clear, then add talcum powder, triethyl citrate and glyceride monostearate in turn, stir for 30 min for standby; Coating: Put the isolation coating pellets into the fluidized bed (Shenzhen Xinyite Technology Co., Ltd, The parameters can be adjusted according to the actual situation to prevent the pellet adhesion.
Seventh, capsule filling
Based on the content of enteric coated pellets, determine the capsule volume and then fill the capsule. Loading capacity: theoretical value±5%, loading capacity difference: ±7.5%.
Stability inspection method: under the conditions of 40±2° C. and 75±5% RH, samples were taken in the month 0, 1, 2 and 3 to test the related substances, acid resistance and release rate. A specific detection method is as follows:
Take an appropriate amount of enteric coated pellets prepared in this Example (about equivalent to 65 mg of obizidine fumarate), weigh it accurately and place in a 25 ml volumetric flask, add an appropriate amount of diluent (DMSO-methanol, 1:4 v/v) to dissolve obizidine fumarate via ultrasound for 15 min, allow it to cool, dilute with diluent to volume to the notch, shake up, centrifuge at 12000 rpm for 10 min, and take the supernatant as the test solution. Accurately measure 1 ml of the test solution and put into a 100 ml volumetric flask, dilute with the diluent to the scale, shake up, and use as the control solution. In addition, take appropriate amount of the reference substance of obizidine fumarate, the reference substance of impurity A, the reference substance of impurity C and triethyl citrate (TEC) respectively, and dilute them with diluent to obtain a mixed solution, each containing about 25 μg of obizidine fumarate, impurity A, impurity C and triethyl citrate per 1 mL.
According to the high performance liquid chromatography (Chinese Pharmacopoeia, 2015 Edition, Part IV, General Rule 0512), octadecyl silane bonded silica gel is used as the filler (recommended chromatographic column: YMC-PACK Pro C18, 4.6 mm×100 mm, 3 μm); take methanol acetonitrile (1:3) as mobile phase B, and take perchlorate buffer solution of pH 2.2 (weigh 7.0 g of sodium perchlorate, add 1000 ml of water to dissolve, adjust the pH to 2.2 with perchloric acid, and filter)−mobile phase B (82:18) as mobile phase A; Perform gradient elution as per Table 2 below; column temperature shall be subject to gradient control according to Table 3 below; The detection wavelength is 210 nm; the flow rate is 1.0 mL per minute.
Take 3 μL of mixed solution to inject into the liquid chromatograph, record the chromatogram with the peak sequence as follow: fumaric acid, impurity A, triethyl citrate, obizidine and impurity C. Take 3 μL of reference solution to inject into the liquid chromatograph, adjust the detection sensitivity, and make the peak height of obizidine about 20%-30% of the full range. Accurately measure 3 μL of blank solution and 3 μL of test solution respectively to inject into the liquid chromatograph, and record the chromatogram. If there is an impurity peak in the chromatogram of the test solution, deduct the chromatographic peak of the blank solution and fumaric acid peak, triethyl citrate peak and impurity C peak in the mixed solution, and after multiplying with the correction factor, the peak area of impurity A (RRT is about 0.22, calculated by the method of correction factor (1.88)) shall not be greater than 0.5 times (0.5%) of the main peak area of the reference solution, The peak area of other single impurities shall not be greater than 0.2 times (0.20%) of the main peak area of the reference solution. Any peak in the chromatogram of the test solution smaller than 0.05 times (0.05%) of the main peak area of the reference solution can be ignored.
Take the enteric coated pellets prepared in this example, and detect according to the method for measuring dissolution and release (Chinese Pharmacopoeia, 2015 Edition, Part IV, first method of General Rule 0931, Method 2). Take 900 ml of hydrochloric acid solution (9-+1000) as dissolution medium, with speed of 100 rpm, run under the rules, and after 120 minutes, the basket is immediately lift out of the liquid level and the hydrochloric acid solution discarded, and then 900 ml of phosphate buffer solution (take 68.05 g of potassium dihydrogen phosphate, add 152 ml of 1 mol/L sodium hydroxide, dilute to 10000 ml with water, shake up, with pH of 6.0) was preheated to 37° C. and added, continue to operate under the rules. After 45 minutes, take the solution and filter it to become the test solution. In addition, accurately weigh 10 mg of obizidine fumarate reference sample, place it in a 100 ml volumetric flask, add ethanol for dissolution, dilute to the scale, and shake up to become the reference solution. Take the test solution and the reference solution to be measured by the method according the concentration, and calculate the dissolution amount of each capsule.
Take the enteric coated pellets prepared in this example as the test sample. According to the method for measuring dissolution and release (the first method of General Rule 0931), take 900 ml of hydrochloric acid solution (9→1000) as the dissolution medium, and the rotational speed is 100 rpm. Operate according to the rule. After 120 minutes, take out the test sample, wash out the hydrochloric acid solution on the surface with water, transfer an appropriate amount of absolute ethanol to a 100 ml measuring flask, and then dissolve the obizidine fumarate with ultrasound for 15 minutes. Placed to cool, dilute to the scale with anhydrous ethanol, shake up, filtered (or centrifuged), take 1 ml of filtrate (or supernatant) into a 10 ml volumetric flask, dilute to the scale with anhydrous ethanol, shake up to be used as the test solution. Determine according to the method according the concentration, and calculate the content of each capsule. The dissolution amount of each capsule is not greater than 10% of the labeled amount.
The stability test results are shown in Table 4.
Conclusion: It can be seen from the data in the above table, after three months of accelerated experiment, 1) the measured impurities are only the degradation impurities 1 of obizidine, and the concentration is very low, indicating that the enteric coated pellets have good stability and drug safety; 2) The acid resistance and release of enteric coated pellets capsule did not change significantly in the accelerated period of 3 months, which further explained the stability of the preparation.
Eight beagles were divided into two groups with four beagles in each group, using a two cycle crossover and self controlled experimental design. Each cycle, capsule T (the content is the enteric coated pellets of obizidine fumarate prepared in Example 1, 100 mg) or capsule R (hydroxypropyl oridazine-β cyclodextrin inclusion complex solution) 10 mL (100 mg). Fast for 12 h before administration, and control drinking water before administration and within 4 h after administration. Take food 5 hours after administration with the wash out period of 7 days. (Note: Preparation method of drug R: appropriate amount of hydroxypropyl-β cyclodextrin is added into 100 mL purified water for dissolution, and 1 g of obizidine fumarate API is added into water, stirred and dissolved to obtain 10 mg/mL inclusion complex, which is divided into 10 portions, 10 mL each).
Blood sample collection: 3 mL to 5 mL of blood was collected from forelimb veins prior to administration (0 h) and after administration at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h. The blood sample was centrifuged at 3000 r/min for 10 min within 15 min after collection, and the plasma was separated. The plasma was transferred to a clean 2 mL EP tube to detect the content of obizidine in the plasma.
The detection method of obizidine in plasma is as follows:
Calculate the measured data of the concentration of oridazine in plasma at each time point after a single administration in beagle dogs, the average concentration (Mean) at each time point, and provide the concentration time curve (C-T curve), average C-T curve, and standard deviation of each time point of the C-T curve for each beagle dog after a single administration of obizidine. The results are shown in Table 5 and
This example is to investigate the compatibility of the enteric coated material with obizidine fumarate. The preparation provided by the invention is enteric coated pellets capsule, which is well absorbed in the duodenum, and the preparation needs to be rapidly released after entering the intestine. Stronger acidity of the enteric coating material, lower pH of dissolution, and better solubility in alkaline conditions, are more favorable to release. But at the same time, the stronger the enteric acid, the more unfavorable the stability of the enteric coated pellets of the invention is, and the greater the thickness of the isolation coating is required. Therefore, to ensure that the enteric coating material can be dissolved at a lower pH, the risk of affecting the stability of the preparation should be minimized.
In this example, the enteric coating material with dissolution pH as close as possible to the duodenal pH range are selected as candidate materials. Acrylic resin (Eudragit L100-55), HPMC-AS (LG), Obaday (enteric coated 91 series PVAP) and Hydroxypropylmethylcellulose phthalate HPMCP (HP-55), which can be dissolved at pH≥5.5, meet the above requirements.
Test method: Weigh {circle around (2)} portions of about 5 mg enteric coating material and 1 portion of API obizidine fumarate, place one portion of the enteric coating material in beaker {circle around (1)} and the other portion in beaker {circle around (2)}, add 100 ml of each configured phosphoric acid buffer salt medium with pH=6.0 into two beakers at the same time, put the two beakers into a 37° C. water bath at the same time, stir at the same time, add API to beaker {circle around (2)} after the enteric coating material is dissolved, and observe the phenomenon. Take cup {circle around (2)} sample to detect the API concentration, and calculate the proportion of its dissolution and interaction amount in the total amount. The results are shown in Table 6.
The complete dissolution in beaker {circle around (1)} of group 1 indicates that 5 mg of Eudragit L100-55 can be completely dissolved in 100 ml of release medium, but precipitation occurs in beaker {circle around (2)}, and the amount of obizidine fumarate detected in the solution is very small, which can be reasonably inferred that there is an interaction between them and the effect is strong. In the same way, it can be seen that groups 2, 3 and 4 also have different degrees of interaction, and the order of strength is as follows: Eubalde (PVAP)>Acrylic resin (Eudragit L100-55)>HPMCP (HP-55)>HPMC-AS (LG). From the perspective of stability and preparation release risk, HPMC-AS is applicable to enteric coated pellets of the invention, followed by HPMCP.
The concentration of alcohol of wetting agent was designed to vary between 50% and 95% to prepare pellets. Taking roundness and disintegration time as the research object, the optimal ethanol concentration was selected. Feed the materials according to the formula in Table 7. Use 75%, 60% and 50% ethanol to manually prepare soft materials. Use an extrusion plate with a hole diameter of 0.9 mm. The extrusion speed is 30 rpm. The extruded materials are rounded in the rotary table. Adjust the rounding parameters according to the material conditions to prepare pellets. The prepared pellets are dried in a fluidized bed (air inlet temperature: material temperature: 35° C.-45° C.) to prepare plain pellets. Observe the roundness of the pellets and determine the disintegration time. The results are shown in Table 7.
The results showed that when the ethanol concentration was 60%, the pellets had good roundness and fast disintegration (30 s). On the premise of ensuring the roundness, 60% ethanol concentration is selected as the wetting agent to ensure rapid disintegration and rapid release of the plain pellets.
Cross linked povidone (XL-10), cross-linked sodium carboxymethyl cellulose and sodium carboxymethyl starch were selected as the objects of study. The conventional maximum dosage was used, and they were used together with low substituted hydroxypropyl cellulose to keep the dosage of other excipients in the prescription unchanged. The dosage of diluent was fine tuned to make the drug loading of pellets consistent. 60% ethanol is used as the wetting agent to manually prepare soft materials. The aperture of the extrusion plate is 0.9 mm, and the extrusion speed is 30 rpm. The extruded materials are rounded in the rotary table. The rounding parameters are adjusted according to the shape of the materials to prepare pellets. The prepared pellets are dried in a fluidized bed (the inlet air temperature is set at 45° C., and the material temperature is controlled at 35° C.-45° C.) to prepare plain pellets. Then HPMC is used to coat the isolation coating. The speed of the fluidized bed inlet fan is 1200 rpm, the speed of the peristaltic pump is 6-12 rpm, the calculated liquid spraying speed is about 0.5-1.4 g/min, the atomization pressure is controlled to be about 0.04 Mpa, and the coating liquid is fully atomized. The material stability is controlled to be 35-45° C., and the weight increase is 3%. Then use HPMC-AS for enteric coating. The speed of the fluidized bed inlet fan is 1200 rpm, the speed of the peristaltic pump is 6-12 rpm, the calculated liquid spraying speed is about 1.1 g-1.7 g/min, the atomization pressure is controlled to be about 0.04 Mpa, and the coating liquid is fully atomized. The material temperature is controlled to be 35° C.-45° C., and the weight gain is 18% (theoretical feeding). The coating formula and process are the same. Test the release and acid resistance of the pellets after filling the capsules, and the results are shown in Table 8.
The results showed that the prescription proportion was the maximum conventional dosage (10% cross-linked povidone (22.22 mg per unit prescription), 8% sodium carboxymethyl starch (17.78 mg per unit prescription), and 6% cross-linked sodium carboxymethyl cellulose (13.33 mg per unit prescription). The release effect of pellets from high to low was sodium carboxymethyl starch (Libeng), sodium carboxymethyl cellulose (Libeng), and cross-linked povidone (XL-10). When sodium carboxymethyl starch (Libeng) was used as the disintegrant, its swelling power was the largest, Enteric coated pellets disintegrate best and release fastest. Therefore, sodium carboxymethyl starch (Libeng) is selected as the disintegrant of this product. Therefore, the C20161108 batch prescription was determined as the target prescription of plain pellets.
The isolation coating can prevent the API from direct contact and interacting with the enteric coating material HPMC-AS, which affects the release and stability of the preparation. API and HPMC-AS can only be prevented from direct contact or contact after penetration after the isolation coat completely wraps the drug loaded plain pellets and reaches a certain thickness. If the barrier is incomplete or too thin, it will cause API and HPMC-AS in the release medium to interact with each other under local high concentration, and slow down the release. The thicker the isolation coat (the greater the weight gain), the weaker this interaction is, and the HPMC itself also has the characteristics of non-ionic surface activity, which is beneficial to the release of the preparation. In addition, the acidity of the enteric coating material is an unstable factor (degradation) of the API, so the weight gain of the isolation coating is beneficial to the stability of the preparation related substances.
The grain size of the plain pellets is about 0.6-1.2 mm, and the surface area is large. It requires a certain coating weight increase to completely wrap the surface of the plain pellets. According to the diameter of the pellets, when the coating weight increase is 6.8%, the surface of the pellets can be completely covered by the isolation clothing. The weight gain of this example is designed to be 7%, 15% and 19%, and the coating effect is investigated. Hydroxypropyl methyl cellulose is selected as the isolation coating material, talcum powder is used as the anti-adhesive (the dosage ratio is 4:1), the speed of the fluidized bed inlet fan is adjusted according to different batches, 1200-1800 rpm, the speed of the peristaltic pump is 6-8, the calculated liquid spraying speed is about 0.7-1.5 g/min, the atomization pressure is about 0.04-0.12 Mpa, and the coating liquid is fully atomized, and the material stability is controlled at 35° C.-45° C. Hydroxypropylmethylcellulose acetate succinate (HPMC-AS) was selected as the enteric coating material, talcum powder as the anti-adhesive, triethyl citrate as the plasticizer, and monostearin as the anti-static material, with the dosage ratio (11.4:3.8:2.8:0.4). The speed of the fluidized bed air inlet fan was 1200-1400 rpm, the speed of the peristaltic pump was 6-12, and the spraying speed was 0.8-1.3 g/min. The coating liquid was fully atomized by controlling the atomization pressure of 0.04-0.06 Mpa. The actual material temperature was controlled at 35° C.-42° C., Weight gain 18%. The enteric coated pellets were tested for release and acid resistance after being filled with capsules, and the results are shown in Table 9.
Obitazine fumarate is unstable under acidic conditions, the enteric coating material is acidic, and the weight gain of the isolation coating affects the integrity and thickness of the isolation coating film. In this example, the weight gain of the isolation coating was investigated, and the isolation coating weight gain that can effectively block the obizidine fumarate and the enteric coated material was screened. The main items to be investigated were concentration, related substances, acid resistance and release. The results are shown in Table 10.
The results show the following:
When the roundness and pellet size distribution of the plain pellets are the same, the greater the coating weight, the thicker the coating layer, and the stronger the acid resistance; The thicker the enteric coated membrane, the slower it will dissolve, and the release of enteric coated pellets will become slower. In order to ensure that the acid resistance meets the requirement, the coating weight gain should be as low as possible to ensure both the release and the stability of the preparation. In this example, three experiments were designed, in which the weight gain of enteric coating was 18%, 22% and 26% respectively, to coat the isolation coating pellets prepared by the same prescription and process. The speed of the fluidized bed inlet fan is 1200-1400 rpm, the speed of the peristaltic pump is 6-12 rpm, the liquid spraying speed is about 0.8-1.2 g/min, the atomization pressure is controlled to be about 0.03-0.24 Mpa, and the coating liquid is fully atomized. The actual material temperature is controlled to be 35° C.-40° C. The acid resistance and release of enteric coated pellets capsules were tested. See Table 11 for the results.
The results show that:
Although particular embodiments and examples are described herein in detail, the above description is provided by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the invention. In particular, it is contemplated by the inventor that various substitutions, alterations, and modifications may be made to the invention without departing from the scope of the invention as claimed.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202010789585.5 | Aug 2020 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2021/108360 | 7/26/2021 | WO |
